From L-R: Latus CSO Jang-Ho Cha, Latus CEO Peter Ghoroghchian and co-founder Beverly Davidson

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

Jang-Ho Cha had no in­ter­est in leav­ing his post at No­var­tis, where he led trans­la­tion­al med­i­cine for the phar­ma gi­ant’s work in neu­ro­science.

But in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.